Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Sanofi isn’t saying how much it is paying for the OTC rights to Tamiflu in the US ... as Tamiflu continues to decline, with the older brand reduced to just $179m in the first quarter of this ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business ... complement its existing portfolio of popular OTC brands such as antihistamine Allegra, non-opioid pain ...

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies ... could finally be able to bring an OTC PDE-5 inhibitor for erectile ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a trial designed to test an over-the-counter version of its erectile ...

In 2022, Sanofi saw strong growth in sales of analgesics as consumers sought to self-treat mild cases of COVID-19, flus and colds. The company has been strategically divesting non-core brands, and the ...

(RTTNews) - Sanofi's Consumer Healthcare division ... from a prescription-only medication to an over-the-counter option. With this decision, the actual use trial can now proceed, marking Cialis ...

Sanofi acquires 2.3% of shares from L’Oréal for €3 billion. Deal to boost Sanofi's earnings per share and shareholder value. Get access to your new suite of high-powered trading tools ...